TGTX

TG Therapeutics Inc

TGTX, USA

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

https://www.tgtherapeutics.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TGTX
stock
TGTX

TG Therapeutics Inc (NASDAQ:TGTX) Nasdaq 100 Etf Biotech Structure Kalkine Media

Read more →
TGTX
stock
TGTX

Bear Alert: Is TGTX stock trending bullish - Dollar Strength & Verified Trade Idea Suggestions baoquankhu1.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$44.5714

Analyst Picks

Strong Buy

5

Buy

1

Hold

0

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

10.62

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

8.11

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

64.37 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very High

38.14 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-14.37 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Medium

0.69

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 70.19% of the total shares of TG Therapeutics Inc

1.

BlackRock Inc

(13.748%)

since

2025/06/30

2.

Vanguard Group Inc

(9.9639%)

since

2025/06/30

3.

iShares Core S&P Small-Cap ETF

(5.0825%)

since

2025/08/31

4.

State Street Corp

(4.8014%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(2.8481%)

since

2025/07/31

6.

iShares Russell 2000 ETF

(2.2037%)

since

2025/08/31

7.

Geode Capital Management, LLC

(2.1999%)

since

2025/06/30

8.

Vanguard Small Cap Index

(2.186%)

since

2025/07/31

9.

ClearBridge Advisors, LLC

(1.9239%)

since

2025/06/30

10.

SPDR® S&P Biotech ETF

(1.4478%)

since

2025/08/31

11.

Soleus Capital Management, L.P.

(1.4143%)

since

2025/06/30

12.

Vanguard Small Cap Growth Index Inv

(1.231%)

since

2025/07/31

13.

Pictet Asset Manangement SA

(1.2022%)

since

2025/06/30

14.

Goldman Sachs Group Inc

(0.9894%)

since

2025/06/30

15.

Hood River Capital Management LLC

(0.9879%)

since

2025/06/30

16.

FMR Inc

(0.9781%)

since

2025/06/30

17.

T. Rowe Price Associates, Inc.

(0.9753%)

since

2025/06/30

18.

Northern Trust Corp

(0.9679%)

since

2025/06/30

19.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9187%)

since

2025/07/31

20.

Fidelity Small Cap Index

(0.9183%)

since

2025/06/30

21.

Morgan Stanley - Brokerage Accounts

(0.884%)

since

2025/06/30

22.

Charles Schwab Investment Management Inc

(0.8297%)

since

2025/06/30

23.

iShares Russell 2000 Growth ETF

(0.8044%)

since

2025/08/31

24.

Vanguard Explorer Inv

(0.7941%)

since

2025/06/30

25.

Wellington Management Company LLP

(0.775%)

since

2025/06/30

26.

Susquehanna International Group, LLP

(0.7614%)

since

2025/06/30

28.

iShares S&P Small-Cap 600 Growth ETF

(0.7354%)

since

2025/08/31

29.

Citadel Advisors Llc

(0.6583%)

since

2025/06/30

30.

Amvescap Plc.

(0.6113%)

since

2025/06/30

31.

Eventide Asset Management, LLC

(0.6016%)

since

2025/06/30

32.

Eventide Healthcare & Life Sciences I

(0.6016%)

since

2025/06/30

33.

Pictet-Biotech P USD

(0.5947%)

since

2025/07/31

34.

Hood River Small-Cap Growth Instl

(0.5885%)

since

2025/06/30

35.

Bank of New York Mellon Corp

(0.5713%)

since

2025/06/30

36.

Vanguard Tax-Managed Small Cap Adm

(0.5601%)

since

2025/07/31

37.

ClearBridge Small Cap Growth A

(0.559%)

since

2025/07/31

38.

ClearBridge Small Cap Growth

(0.5529%)

since

2025/07/31

39.

Fidelity Select Biotechnology

(0.5007%)

since

2025/07/31

40.

Fidelity Extended Market Index

(0.4604%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.3271

Latest Release

Date

2025-09-30

EPS Actual

2.43

EPS Estimate

0.22

EPS Difference

2.21

Surprise Percent

1004.5455%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(9.5)
GARP
Strong GARP(7)
Growth
Moderate Growth(6)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
High Quality(7.5)
Value
Undervalued(7)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.